These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 34196068)

  • 1. Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health.
    Chang E; Pelosof L; Lemery S; Gong Y; Goldberg KB; Farrell AT; Keegan P; Veeraraghavan J; Wei G; Blumenthal GM; Amiri-Kordestani L; Singh H; Fashoyin-Aje L; Gormley N; Kluetz PG; Pazdur R; Beaver JA; Theoret MR
    Oncologist; 2021 Oct; 26(10):e1786-e1799. PubMed ID: 34196068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of biomarker defined subgroups in FDA approvals of PD-1/PD-L1 inhibitors 2014 to 2020.
    Kim MS; Xu A; Haslam A; Prasad V
    Int J Cancer; 2022 Jun; 150(11):1905-1910. PubMed ID: 35182072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Companion and Complementary Diagnostics-Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Hersom M; Jørgensen JT
    Ther Drug Monit; 2018 Feb; 40(1):9-16. PubMed ID: 29084031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.
    Davis AA; Patel VG
    J Immunother Cancer; 2019 Oct; 7(1):278. PubMed ID: 31655605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics.
    Twomey JD; Zhang B
    AAPS J; 2021 Mar; 23(2):39. PubMed ID: 33677681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
    Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
    Suzman DL; Agrawal S; Ning YM; Maher VE; Fernandes LL; Karuri S; Tang S; Sridhara R; Schroeder J; Goldberg KB; Ibrahim A; McKee AE; Pazdur R; Beaver JA
    Oncologist; 2019 Apr; 24(4):563-569. PubMed ID: 30541754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis.
    Khan M; Du K; Ai M; Wang B; Lin J; Ren A; Chen C; Huang Z; Qiu W; Yuan Y; Tian Y
    Front Immunol; 2023; 14():1060308. PubMed ID: 36949944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC.
    Jørgensen JT
    Expert Rev Mol Diagn; 2016; 16(2):131-3. PubMed ID: 26559787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
    Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
    JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on companion and complementary diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC.
    Jørgensen JT
    Expert Rev Mol Diagn; 2021 May; 21(5):445-454. PubMed ID: 33896308
    [No Abstract]   [Full Text] [Related]  

  • 15. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics.
    Akinleye A; Rasool Z
    J Hematol Oncol; 2019 Sep; 12(1):92. PubMed ID: 31488176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
    Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
    Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
    Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
    Fashoyin-Aje L; Donoghue M; Chen H; He K; Veeraraghavan J; Goldberg KB; Keegan P; McKee AE; Pazdur R
    Oncologist; 2019 Jan; 24(1):103-109. PubMed ID: 30120163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of efficacy discrepancy between early-phase clinical trials and phase III trials of PD-1/PD-L1 inhibitors.
    Li X; Zhou Y; Xu B; Qin Y; Zhao J; Li M; Xu J; Li G
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38233100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Companion and Complementary Diagnostics: Clinical and Regulatory Perspectives.
    Jørgensen JT
    Trends Cancer; 2016 Dec; 2(12):706-712. PubMed ID: 28741518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.